Expression of HLA-DR antigen and smooth muscle cell differentiation markers by valvular fibroblasts in degenerative aortic stenosis

Department of Cardiology, Institution of Medicine, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden.

OBJECTIVES. This study was designed to analyze the functional characteristics of fibroblasts present in aortic valves with degenerative stenosis. BACKGROUND. Morphologic analysis of degenerative stenosis of tricuspid aortic valves has revealed an extensive interstitial fibrosis. METHODS. Stenotic aortic valves collected during aortic valve replacement and control valves collected at autopsy were fixed in formaldehyde, cryosectioned and stained with antibodies against leukocyte markers, HLA-DR and intracellular filaments. Fibroblasts isolated from stenotic valve and skin explants were grown in cell culture, and their proliferative activity was analyzed by cell counting and uptake of tritiated thymidine. RESULTS. In the stenotic valves nearly all interstitial cells expressed vimentin, and approximately 60% of the cells also expressed alpha-actin and desmin. HLA-DR was present on inflammatory cells as well as on one-third of the fibroblast-like cells in the interstitium. Macrophages were found in the interstitium and T lymphocytes close to calcium deposits and in subendothelial areas. In control valves, fibroblasts expressed vimentin but not alpha-actin or desmin. Few inflammatory cells were present in these valves, and HLA-DR expression was restricted to the endothelial surface. In culture, stenotic valve fibroblasts had a reduced ability to proliferate in serum and to activate DNA synthesis in response to growth factors compared with skin fibroblasts from the same patient. CONCLUSIONS. The observation that fibroblasts present in aortic valves with degenerative stenosis express smooth muscle cell characteristics and HLA-DR antigen and show signs of cellular senescence in vitro suggests that they are in a state of chronic activation similar to that observed in fibromatosis and scleroderma lesions.

This article has been cited by other articles:

				A. B. Rossebo, T. R. Pedersen, K. Boman, P. Brudi, J. B. Chambers, K. Egstrup, E. Gerdts, C. Gohlke-Barwolf, I. Holme, Y. A. Kesaniemi, et al. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis N. Engl. J. Med., September 25, 2008; 359(13): 1343 - 1356. [Abstract] [Full Text] [PDF]

				D. S. Owens, R. Katz, E. Johnson, D. M. Shavelle, J. L. Probstfield, J. Takasu, J. R. Crouse, J. J. Carr, R. Kronmal, M. J. Budoff, et al. Interaction of Age With Lipoproteins as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis Arch Intern Med, June 9, 2008; 168(11): 1200 - 1207. [Abstract] [Full Text] [PDF]

				M. Pho, W. Lee, D. R. Watt, C. Laschinger, C. A. Simmons, and C. A. McCulloch Cofilin is a marker of myofibroblast differentiation in cells from porcine aortic cardiac valves Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1767 - H1778. [Abstract] [Full Text] [PDF]

				S. Helske, M. Laine, M. Kupari, J. Lommi, H. Turto, L. Nurmi, I. Tikkanen, K. Werkkala, K. A. Lindstedt, and P. T. Kovanen Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves Eur. Heart J., August 1, 2007; 28(15): 1894 - 1903. [Abstract] [Full Text] [PDF]

				H. D. Wu, M. S. Maurer, R. A. Friedman, C. C. Marboe, E. M. Ruiz-Vazquez, R. Ramakrishnan, A. Schwartz, M. D. Tilson, A. S. Stewart, and R. Winchester The Lymphocytic Infiltration in Calcific Aortic Stenosis Predominantly Consists of Clonally Expanded T Cells J. Immunol., April 15, 2007; 178(8): 5329 - 5339. [Abstract] [Full Text] [PDF]

				K. D. O'Brien Pathogenesis of Calcific Aortic Valve Disease: A Disease Process Comes of Age (and a Good Deal More) Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1721 - 1728. [Abstract] [Full Text] [PDF]

				S. Helske, S. Syvaranta, M. Kupari, J. Lappalainen, M. Laine, J. Lommi, H. Turto, M. Mayranpaa, K. Werkkala, P. T. Kovanen, et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves Eur. Heart J., June 2, 2006; 27(12): 1495 - 1504. [Abstract] [Full Text] [PDF]

				R. Katz, N. D. Wong, R. Kronmal, J. Takasu, D. M. Shavelle, J. L. Probstfield, A. G. Bertoni, M. J. Budoff, and K. D. O'Brien Features of the Metabolic Syndrome and Diabetes Mellitus as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis Circulation, May 2, 2006; 113(17): 2113 - 2119. [Abstract] [Full Text] [PDF]

				R. V. Freeman and C. M. Otto Spectrum of Calcific Aortic Valve Disease: Pathogenesis, Disease Progression, and Treatment Strategies Circulation, June 21, 2005; 111(24): 3316 - 3326. [Full Text] [PDF]

				K. D. O'Brien, J. L. Probstfield, M. T. Caulfield, K. Nasir, J. Takasu, D. M. Shavelle, A. H. Wu, X.-Q. Zhao, and M. J. Budoff Angiotensin-Converting Enzyme Inhibitors and Change in Aortic Valve Calcium Arch Intern Med, April 25, 2005; 165(8): 858 - 862. [Abstract] [Full Text] [PDF]

				S. Helske, K. A. Lindstedt, M. Laine, M. Mayranpaa, K. Werkkala, J. Lommi, H. Turto, M. Kupari, and P. T. Kovanen Induction of local angiotensin II-producing systems in stenotic aortic valves J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1859 - 1866. [Abstract] [Full Text] [PDF]

				G. A. Walker, K. S. Masters, D. N. Shah, K. S. Anseth, and L. A. Leinwand Valvular Myofibroblast Activation by Transforming Growth Factor-{beta}: Implications for Pathological Extracellular Matrix Remodeling in Heart Valve Disease Circ. Res., August 6, 2004; 95(3): 253 - 260. [Abstract] [Full Text] [PDF]

				K.-L. Chan Is aortic stenosis a preventable disease? J. Am. Coll. Cardiol., August 20, 2003; 42(4): 593 - 599. [Abstract] [Full Text] [PDF]

				K. D. O'Brien, D. M. Shavelle, M. T. Caulfield, T. O. McDonald, K. Olin-Lewis, C. M. Otto, and J. L. Probstfield Association of Angiotensin-Converting Enzyme With Low-Density Lipoprotein in Aortic Valvular Lesions and in Human Plasma Circulation, October 22, 2002; 106(17): 2224 - 2230. [Abstract] [Full Text] [PDF]

				F. Robicsek, M. J. Thubrikar, and A. A. Fokin Cause of degenerative disease of the trileaflet aortic valve: review of subject and presentation of a new theory Ann. Thorac. Surg., April 1, 2002; 73(4): 1346 - 1354. [Abstract] [Full Text] [PDF]

				C. M. Otto, B. K. Lind, D. W. Kitzman, B. J. Gersh, D. S. Siscovick, and The Cardiovascular Health Study Association of Aortic-Valve Sclerosis with Cardiovascular Mortality and Morbidity in the Elderly N. Engl. J. Med., July 15, 1999; 341(3): 142 - 147. [Abstract] [Full Text] [PDF]

				M. Olsson, J. Thyberg, and J. Nilsson Presence of Oxidized Low Density Lipoprotein in Nonrheumatic Stenotic Aortic Valves Arterioscler. Thromb. Vasc. Biol., May 1, 1999; 19(5): 1218 - 1222. [Abstract] [Full Text] [PDF]

				C. M. Otto, I. G. Burwash, M. E. Legget, B. I. Munt, M. Fujioka, N. L. Healy, C. D. Kraft, C. Y. Miyake-Hull, and R. G. Schwaegler Prospective Study of Asymptomatic Valvular Aortic Stenosis : Clinical, Echocardiographic, and Exercise Predictors of Outcome Circulation, May 6, 1997; 95(9): 2262 - 2270. [Abstract] [Full Text]

				K. D. O'Brien, D. D. Reichenbach, S. M. Marcovina, J. Kuusisto, C. E. Alpers, and C. M. Otto Apolipoproteins B, (a), and E Accumulate in the Morphologically Early Lesion of `Degenerative' Valvular Aortic Stenosis Arterioscler. Thromb. Vasc. Biol., April 1, 1996; 16(4): 523 - 532. [Abstract] [Full Text]